Kura Oncology, Inc. (KURA)

NMS – Real vaqt narxi. Valyuta: USD

9.68

+0.17 (1.79%)

Yopilishda: May 12, 2026, 4:00 PM EDT

9.02

-0.66 (-6.82%)

Bozor oldidan: May 13, 2026, 9:08 AM EDT

13.05.2026

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

13.05.2026

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management's earnings call for the first quarter of 2026.

12.05.2026

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.66 per share a year ago.

12.05.2026

Kura Oncology Reports First Quarter 2026 Financial Results

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported first quarter 2026 financial results and provided a corporate update.

12.05.2026

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –

06.05.2026

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura management is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2026.

05.05.2026

Kura Oncology to Report First Quarter 2026 Financial Results

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Kura Oncology Reports First Quarter 2026 Financial Results

06.05.2026

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

04.05.2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 133,750 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

24.04.2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –

Kura Oncology, Inc. (KURA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Search stocks

Kura Oncology, Inc. (KURA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology to Report First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML